Study ID,Age,Gender,Primary Melanoma type,M stage,Priors,Therapy,Response duration,LDH,BRAF,OS,Biopsy,Censored
CR04885,49,F,cutaneous,IIIc,0,Tremelimuma b 15x4,85,not available,"WT BRAF; WT NRAS",2.1,pre,1
CR06670,79,F,cutaneous,IIIc,0,Tremelimuma b 15x4,168,not available,BRAF V600K,3.7,post,0
CR22640,71,M,cutaneous,M1c,1,3x4,216,not available,"WT BRAF; WT NRAS",4.3,pre,1
CR6126,66,F,cutaneous,M1b,1,3x4,101,211,NRAS Q61K,1.9,pre,1
CR6161,81,M,cutaneous,M1b,0,3x4,136,not available,NRAS Q61L,2.6,pre,0
CRNR0244,49,M,unknown,M1c,0,3x4,109,180,BRAF V600E,2.1,post,1
CRNR2472,71,M,cutaneous,M1c,0,randomized 3 vs 10 x4,89,129,"WT BRAF; NRAS",1.7,post,1
CRNR4941,40,F,unknown,M1c,0,10x20 then 3x1,376,not available,"WT BRAF; NRAS",7.2,post,1
LSD0167,33,M,cutaneous,M1c,0,3x3,140,156,BRAF V600E,2.7,pre,1
LSD2057,36,F,cutaneous,M1c,0,3x4,64,327,BRAF V600E,3.3,pre,1
LSD3484,74,M,cutaneous,M1c,1,3x4,154,664,"WT BRAF; NRAS",2.9,pre,1
LSD4691,62,M,cutaneous,M1c,2,3x14,383,not available,"WT BRAF; NRAS",7.3,post,1
LSD4744,52,M,cutaneous,M1c,0,3x7,80,250,NRAS Q61K,2.1,pre,1
LSD6819,55,M,acral,M1c,0,3x3,67,178,BRAF V600E,3.4,pre,1
LSDNR1120,68,M,unknown,M1a,0,10x13,242,178,NRAS Q61R,4.6,pre,1
LSDNR1650,71,F,uveal,M1c,0,3x7,73,286,"WT BRAF; NRAS",2.7,post,0
LSDNR9298,82,F,cutaneous,M1c,1,3x4,217,232,BRAF L597R,4.2,post,1
NR2137,18,M,cutaneous,M1c,0,3x4,8,293,BRAF V600E,0.8,pre,0
NR4018,55,M,not available,M1C,YES,10X4,11,not available,BRAF V600K,0.3,pre,0
NR4045,42,M,cutaneous,M1c,0,3x4,11,237,BRAF V600E,1.7,post,0
NR4083,54,M,not available,M1C,0,3X4,12,not available,NRAS Q61K,0.2,pre,0
NR4631,59,M,cutaneous,M1c,1,3x4,13,341,"WT BRAF; NRAS",0.5,post,0
NR6689,46,F,cutaneous,M1c,2,3X4,11,209,"WT BRAF; WT NRAS",1.2,post,0
NR6721,64,M,cutaneous,M1a,2,10x4,3,144,NRAS Q61R,0.8,post,0
NR6842,64,M,cutaneous,M1c,0,3x4 then 3x3,12,176,"WT BRAF; WT NRAS",0.8,pre,0
NR8815,67,F,cutaneous,M1b,3,3x4,9,180,BRAF S363F,1.2,post,0
NR9445,50,M,cutaneous,M1c,0,3x3+vem,8,2502,BRAF V600E,0.2,pre,0
NR9449,64,F,cutaneous,M1c,0,3x4,10,202,NRAS Q61R,0.6,post,0
NR9521,74,M,cutaneous,M1b,0,3x4,12,169,NRAS Q61L,2.7,post,0
NR9705,63,F,acral,M1c,0,3x4,29,167,BRAF V600E,1.2,post,0
NR9765,38,F,cutaneous,M1b,1,3x4 then,22,187,BRAF V600E,2.1,pre,0
PR03803,90,M,cutaneous,IIIc,2,Tremelimumab 10x6,236,not available,BRAF A652T,7.9,post,0
PR12117,66,M,cutaneous,M1c,0,Tremelimumab 15x4,73,not available,BRAF V600K,1.6,pre,0
PR4035,78,M,not available,M1c,YES,3X6,218,not available,BRAF G469E,4.2,pre,1
PR4046,44,M,not available,M1a,YES,10X5,110,not available,BRAF V600E,2.1,pre,1
PR4077,75,M,not available,M1c,YES,10X4,316,not available,"WT BRAF; WT NRAS",6.1,pre,1
PR4091,65,F,not available,M1a,YES,3X4,314,not available,BRAF V600E,6.0,pre,1
PR4092,57,F,not available,M1a,YES,10X4,315,not available,BRAF V600E,6.1,pre,1
LSDNR3086,43,M,cutaneous,M1c,2,randomized 0.3 - 3 or 10x4; 10x10,135,not available,BRAF V600E,2.6,post,0
